ETNB - 89bio, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.17
DETAILS
HIGH:
$25.00
LOW:
$12.00
MEDIAN:
$14.50
CONSENSUS:
$17.17
UPSIDE:
15.70%
About 89bio, Inc. (https://www.89bio.com)
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Rohan Palekar | Chief Executive Officer & Director | 1966 | $999,834 USD |
| Harry Mansbach | Chief Medical Officer | 1965 | $717,383 USD |
| Quoc Le-Nguyen | Chief Technical Officer | 1968 | $693,099 USD |
| Ryan Stephen Martins | Chief Financial Officer | 1978 | $646,525 USD |
| Francis W. Sarena | Chief Operating Officer | 1971 | $590,473 USD |
| Amanda Kurihara | Vice President of People & Culture | – | – |
| Annie J. Chang | Vice President of Investor Relations & Corporate Communications | – | – |
| Melissa Abel | Senior Vice President of Commercial Strategy | – | – |
| Michael Baldwin | Senior Vice President & Head of Quality | – | – |
| Shiva K. Natarajan | Senior Vice President of Finance & Principal Accounting Officer | 1966 | – |
| Teresa Perney | Chief Regulatory & Quality Officer | – | – |